ClinicalTrials.gg
RecruitingNCT07019220COBRAUpdated Jun 13, 2025

Chemoablation for Low-Grade Bladder Cancer

A Phase 2 interventional study of Gemcitabine in Bladder (Urothelial, Transitional Cell) Cancer, sponsored by Ekaterina Laukhtina. Recruiting at 1 site in Austria. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Ekaterina Laukhtina · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Dec 2023, registered Jun 2025).
  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.

Read the detailed description

In this study, patients with histologically confirmed Ta low-grade bladder cancer will undergo chemoablation with gemcitabine (six weekly instillations). The study aims to evaluate the efficacy, safety, and tolerability of chemoablation.

02

Conditions studied

  • Bladder (Urothelial, Transitional Cell) Cancer

Keywords

  • Non-Muscle Invasive Bladder Cancer
  • Intravesical Therapy
  • Non-Surgical Treatment
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 47 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Ekaterina Laukhtina is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male/female participants who are at least 18 years of age on the day of providing documented will be enrolled in this study
  • Diagnosis of a recurrent tumor and a history of TaLG BCa or diagnosis of primary TaLG BCa confirmed by cold cup at screening or within 8 weeks before screening
  • On screening cystoscopy: Diameter of the largest lesion ≤15mm
  • Number of lesions ≤5
  • Cystoscopy with bladder diagram including number, site, size and appearance of the tumors with photo documentation
  • Patient who has recurrence of and not other than TaLG NMIBC (low or intermediate EAU risk)
  • NMIBC requiring treatment with transurethral resection of bladder tumors (TURBT)
  • Negative voiding cytology for high grade (HG) disease within 8 weeks before Screening
  • No lymph node or distant metastasis
  • Male and female patients must use an effective method during the study and for a minimum of 6 months after study treatment
  • Female patients of must have a negative serum pregnancy test within 2 weeks prior to enrollment. Female patients of childbearing potential must use adequate contraception during study period
  • Willing and able to provide informed consent

Exclusion criteria

Exclusion Criteria:

  • Tumors that clinicians suspect to be HG
  • Positive HG cytology according to Paris criteria
  • Diameter of tumor >15 mm
  • Number of lesions >5
  • Any previous intravesical therapy within 1 year
  • Previous HG NMIBC (within the last 3 years). It is allowed to include patients who had history of HG disease longer than 3 years ago.
  • Past or current muscle invasive bladder cancer (i.e., T2, T3, T4) or UC
  • History of upper tract urothelial carcinoma (UTUC)
  • urethral stricture that would preclude passage of a urethral catheter
  • History of neurogenic bladder; active urinary retention; any other condition that would prohibit normal voiding
  • Evidence of active urinary tract infection (UTI) that in the Investigator's opinion cannot be treated and resolved prior to and/or administration of study treatment
  • Patient refused to participate
  • Known positive (HIV) test.
  • Female patients who are pregnant/breastfeeding.
  • Female patients of not using adequate .
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Patients with low-grade NMIBC

    Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Clinical complete response (cCR)

    cCR defined as negative urine cytology and absence of macroscopic tumor at the cystoscopic evaluation

    Time frame: From the end of treatment (EOT) visit to the follow-up visits (1 and 3 months post-treatment).

Secondary outcomes

  1. Pathological complete response (pCR)

    pCR defined as negative urine cytology, absence of macroscopic tumor at cystoscopic evaluation and confirmed by negative biopsy/TURB

    Time frame: From the end of treatment visit (EOT) to the follow-up visits (1 and 3 months post-treatment).

  2. Patient-reported Outcomes based on EORTC QLQ-NMIBC24

    The global health status/quality of life endpoint will be based on the scales of EORTC QLQ-NMIBC24 questionnaire.

    Time frame: Will be measured weekly during treatment period, at the end of treatment visit and follow-up visits (1 and 3 months post-treatment).

  3. Patient-reported Outcomes based on EORTC QLQ-C30

    The global health status/quality of life endpoint will be based on the scales of EORTC QLQ-C30 questionnaire.

    Time frame: Will be measured weekly during treatment period, at the end of treatment visit and follow-up visits (1 and 3 months post-treatment).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Brausi MA, Gontero P, Altieri V, Colombo R, Conti I, Bono AV. Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study. Urol Int. 2011;87(4):470-4. doi: 10.1159/000331727. Epub 2011 Nov 11. PubMed 22086229 ↗
  • Gardmark T, Carringer M, Beckman E, Malmstrom PU; Members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology. 2005 Sep;66(3):527-30. doi: 10.1016/j.urology.2005.03.084. PubMed 16140071 ↗
  • Maffezzini M, Campodonico F, Canepa G, Capponi G, Fontana V. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol. 2007 Apr;51(4):956-61. doi: 10.1016/j.eururo.2006.08.038. Epub 2006 Sep 20. PubMed 17027141 ↗
  • Campodonico F, Canepa G, Capponi G, Bozzo L, Maffezzini M. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability. Anticancer Res. 2005 May-Jun;25(3c):2381-4. PubMed 16080464 ↗
  • Serretta V, Galuffo A, Pavone C, Allegro R, Pavone-MacAluso M. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology. 2005 Jan;65(1):65-9. doi: 10.1016/j.urology.2004.08.027. PubMed 15667865 ↗
  • Gontero P, Casetta G, Maso G, Sogni F, Pretti G, Zitella A, Frea B, Tizzani A. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol. 2004 Sep;46(3):339-43. doi: 10.1016/j.eururo.2004.05.001. PubMed 15306105 ↗

Individual participant data

Plan to share: No — The data collected in this study includes sensitive patient information related to medical history, treatment responses, and clinical outcomes. To protect patient confidentiality and comply with ethical guidelines and institutional policies, individual participant data will not be shared publicly

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2027, 47 months after the start.

Of 337 non-industry phase 2 interventional studies under Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 99. This study's planned 47 months is below that.

Counting every sponsor, half of 517 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 13, 2025
StartActual
Dec 27, 2023
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07019220
Lead sponsor
Ekaterina Laukhtina
Responsible party
Ekaterina Laukhtina (Dr., Medical University of Vienna) — Sponsor-investigator
First posted
Jun 13, 2025
Start date
Dec 27, 2023
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Jun 13, 2025

Study contacts

Ekaterina Laukhtina Dr., Medical Doctor
Contact
ekaterina.laukhtina@meduniwien.ac.at
+43 (0)1 40400-26315
Shahrokh F. Shariat Prof. Dr., Professor
principal investigator · Department of Urology, Medical University of Viernna

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion